Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545830 · ClinicalTrials.gov registry record · Phase 2
Metabolic Syndrome and Insulin Resistance at Allina
A Phase 2 study, sponsored by Allina Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT01545830 is a Phase 2 study that has completed, run by Allina Health System. The registered enrollment target is 84 participants.
The verdict
NCT01545830, a Phase 2 study, has completed, sponsored by Allina Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
Vitamin D deficiency is widespread and appears to represent one easily and inexpensively modifiable risk factor for diabetes and cardiovascular disease. More than 40 years of data link hypovitaminosis D to metabolic syndrome, insulin resistance, hyperglycemia, type 2 diabetes and increased cardiovascular risk. Screening for vitamin D deficiency followed by supplementation in appropriate individuals could be among the simplest and most cost-effective measures for reducing metabolic syndrome and insulin resistance in the general population. This study will test the hypothesis that increasing vitamin D status in vitamin D deficient individuals with metabolic syndrome will: 1. reduce multiple serum cardiometabolic risk factors for both diabetes and cardiovascular disease, 2. stabilize or reverse the stage of pre-diabetes, 3. improve quality of life, and, 4. improve the ability to make health-related behavioral changes.
Interventions
- DIETARY_SUPPLEMENT vitamin D3 (cholecalciferol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01545830
The ClinicalTrials.gov registry entry for NCT01545830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allina Health System, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vitamin D3 (cholecalciferol) is the first listed.
NCT01545830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01545830 about?
NCT01545830 is a clinical study titled "Metabolic Syndrome and Insulin Resistance at Allina". Vitamin D deficiency is widespread and appears to represent one easily and inexpensively modifiable risk factor for diabetes and cardiovascular disease. More than 40 years of data link hypovitaminosis D to metabolic syndrome, insulin resistance, hyperglycemia, type 2 diabetes and increased cardiovas...
What is the current status of trial NCT01545830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2012-03. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01545830?
The interventions under investigation include: vitamin D3 (cholecalciferol) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01545830?
This trial is sponsored by Allina Health System, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.